Evaluation of the effect and safety of recombinant human erythropoietin (ior (R)EPOCIM ) as a cardioprotective agent in the surgery of rheumatic valvular disease.

Next Previous
Trial Profile

Evaluation of the effect and safety of recombinant human erythropoietin (ior (R)EPOCIM ) as a cardioprotective agent in the surgery of rheumatic valvular disease.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Recombinant erythropoietin (Primary)
  • Indications Rheumatic disorders
  • Focus Adverse reactions

    • Most Recent Events

    • 29 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top